Nektar's Rezpegaldesleukin Shows Promising Long-Term Efficacy in Atopic Dermatitis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy NKTR?
Source: NASDAQ.COM
- Durable Efficacy: Nektar Therapeutics reported that in the REZOLVE-AD Phase 2b study, 71% and 83% of patients maintained EASI-75 responses after 52 weeks of treatment with Rezpegaldesleukin, indicating its durable efficacy in moderate-to-severe atopic dermatitis patients.
- New Responses: During the 36-week maintenance phase, some patients achieved new or deeper responses, with EASI-100 response rates showing up to a five-fold increase, highlighting the drug's potential advantages in treatment outcomes.
- Favorable Safety Profile: Nektar noted that the safety profile of Rezpegaldesleukin remained consistent with earlier findings, with most adverse events being mild or moderate and low discontinuation rates across both dosing regimens, enhancing its clinical applicability.
- Future Development Plans: Nektar plans to advance Rezpegaldesleukin into Phase 3 studies with a goal of submitting a Biologics License Application (BLA) by 2029, demonstrating the company's confidence in the drug's market potential and therapeutic value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 75.710
Low
102.00
Averages
123.43
High
165.00
Current: 75.710
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns regarding the company's compliance and operations.
- Allegations of False Statements: The complaint alleges that Nektar's executives made materially false and misleading statements during the class period, particularly regarding the enrollment and results of the REZOLVE-AA trial, which may have led investors to misjudge the company's prospects.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal system's role in protecting investor rights.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only upon successful recovery, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Nektar Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to discuss their rights and ensure proper representation in the class action, avoiding the risk of being an absent class member.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered losses, highlighting significant failures in the company's disclosure practices that could have long-term negative effects on its stock price and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results.
- Investor Rights Protection: Investors have until May 5, 2026, to apply as Lead Plaintiff in the class action, with Pomerantz LLP emphasizing its expertise in securities fraud and corporate misconduct to advocate for victim compensation.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, indicating significant deficiencies in the company's information disclosure practices, which may lead to future legal and financial repercussions.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Nektar Therapeutics investors of a class action lawsuit for those who purchased securities between February 26, 2026, and December 12, 2025, with a deadline of May 5, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Impact: Nektar's stock price fell nearly 8% on December 16, 2025, following disappointing topline results from its Phase 2b REZOLVE-AA trial, which narrowly missed statistical significance, undermining investor confidence and affecting the company's future market performance.
- Trial Integrity Concerns: The lawsuit alleges that Nektar failed to disclose that enrollment did not adhere to applicable instructions and protocol standards, likely leading to significant negative impacts on the study's findings, thus misleading investors about the trial's prospects.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to help investors pursue claims for losses caused by corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors, showcasing their strength in such cases.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, aiming to recover damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns regarding the company's compliance and operations.
- Allegations of False Statements: The complaint alleges that Nektar's executives made materially false and misleading statements during the class period, particularly regarding the enrollment and results of the REZOLVE-AA trial, which may have led investors to misjudge the company's prospects.
- Investor Call to Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal system's role in protecting investor rights.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only upon successful recovery, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Nektar Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Issue: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to discuss their rights and ensure proper representation in the class action, avoiding the risk of being an absent class member.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered losses, highlighting significant failures in the company's disclosure practices that could have long-term negative effects on its stock price and investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California, representing investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable standards, which could significantly impact trial results.
- Investor Rights Protection: Investors have until May 5, 2026, to apply as Lead Plaintiff in the class action, with Pomerantz LLP emphasizing its expertise in securities fraud and corporate misconduct to advocate for victim compensation.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in the REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial outcomes, while the company overstated the integrity of the trial, resulting in investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, indicating significant deficiencies in the company's information disclosure practices, which may lead to future legal and financial repercussions.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the Nektar class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses once the true information was disclosed.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this legal domain.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Nektar Therapeutics investors of a class action lawsuit for those who purchased securities between February 26, 2026, and December 12, 2025, with a deadline of May 5, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Impact: Nektar's stock price fell nearly 8% on December 16, 2025, following disappointing topline results from its Phase 2b REZOLVE-AA trial, which narrowly missed statistical significance, undermining investor confidence and affecting the company's future market performance.
- Trial Integrity Concerns: The lawsuit alleges that Nektar failed to disclose that enrollment did not adhere to applicable instructions and protocol standards, likely leading to significant negative impacts on the study's findings, thus misleading investors about the trial's prospects.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations to help investors pursue claims for losses caused by corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors, showcasing their strength in such cases.
See More
